Dr Kyriakos Kalogerakos has completed his Degree in Medical School from the Aristotle University Thessaloniki in June 1986. He is currently a Director and Chairman of Breast Unit of Metaxa Hospital.`His scientific work is on the subject “ The behavior of cancer markers in blood serum and bile in neoplasms of the gastrointestinal tract ”

Breast cancer

Dr. Bhattacharjee did her B.Sc in Biotechnology from Bangalore University in 2006 and M.Sc in Applied Genetics from Bangalore University in 2008. She then moved to England to pursue her DPhil (Phd) in Biochemistry from Oxford University where she studied the role of Fml1 and its partner proteins Mhf1 and Mhf2 in promoting genome stability. She was awarded her DPhil in 2012. During her time at Oxford, she was also a tutor at Greene’s College, Oxford. In 2013, Dr. Bhattacharjee moved to Cold Spring Harbor Laboratory, New York. At CSHL, her work has focused on understanding the epigenetic regulation of DNA repair. She is also an academic tutor at the Watson School of Biological studies, the school for graduate studies at CSHL

Bio chemistry

Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, Synchrocyclotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc. He has participated at more than three hundreds reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI) Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, New Zealand, Scotland, Ireland, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Ukraine, Turkey, France, Swiss, Germany, Sweden, Norway, Italy, Austria, Czech Republic, Hungary, Poland, South Africa, Egypt, Brazil, Spain, Portugal, Mexico, Japan, Singapore, Malaysia, Thailand, Taiwan, Hong Kong, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor and so on heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than nine hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than three hundreds reputed international academic–scientific–research 2 institutes around the world. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the Bio Spectroscopy Core Research Laboratory at California South University (CSU), Irvine, California, USA.

Biophysical Chemistry, bio molecular Spectroscopy, Quantum Chemistry, Nano chemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modeling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, Synchrocyclotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hyper methylation & Hypo methylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells

Dr Silvia Paola Corona has completed her PhD from Melbourne University (Australia). Silvia Paola is currently a medical doctor/researcher at the Breast Surgery Division of the European Institute of Oncology, in Milan, a wordly renowned institute. She has published papers and served as reviewer in international peer-reviewed journals.

Breast Cancer surgery, targeted therapies and genetics.

Professor Fleming is a direct descendant of Rollo. He was born in Cedar Falls, IA and received his Doctorate in Particle Physics through the JFK administration. He has additional degrees in Biology, Chemistry, Psychology, Medicine and Law. He is specifically trained as a Nuclear and Preventive Cardiologist in addition to Nuclear Imaging. He is one of three Physicians in the world Certified in PET Imaging and the only American. He is the founder of the theory of "Inflammation and Heart Disease" and is considered by many to be the Father of Modern Nuclear Cardiology and Nuclear Medicine since his development of the first truly quantitative AI system for detection and treatment monitoring of Heart Disease & Cancer. He has published more than 150 papers in the field, reviews for more than a dozen peer reviewed medical journals, has published three books, 8 chapters in medical textbooks and been Editor-in-Chief of the medical textbook "Establishing Better Standards of Care in Doppler Echocardiography, Computed Tomography and Nuclear Cardiology."

Heart Disease, Cancer, Nuclear Cardiology, Nuclear Medicine

Professor Charles Coombes, Professor of Medical Oncology, Imperial College London. He is also Hon Consultant Medical Oncologist, Imperial College Healthcare Trust.From October 2010 Professor Coombes is Director of The Imperial CRUK Cancer Centre. He is also Chair of The Imperial Cancer Research (UK) Centre Steering Committee and Theme leader for Cancer, Imperial College London.

He is engaged in developing novel methods for prediction of response to endocrine therapy in breast cancer and also carrying out research aimed at understanding the mechanisms of resistance to endocrine therapy and development of novel anti-cancer drugs.

In his capacity as Head of Division of Cancer until 30 September 2012, he was responsible for the running of the division, as well as the recruitment and retention of staff. He is personally responsible for running the section of Cancer Cell Biology and has three CRUK Programme Grants and many other project and smaller grants. This department currently has more than 280 scientific staff. The department has doubled in size over the past three years and now has and I4 Professors and twenty sections.

His laboratory is focusing on elucidating molecular signals controlling aberrant growth of breast cancer cells with specific focus on the oestrogen receptor and allied cell signalling pathways. He works with scientists engaged in molecular target identification and chemists whose remit is to target specific signalling abnormalities to develop novel therapies for breast cancer. He also runs a translational laboratory which focuses on detection of micrometastatic disease and application to the treatment of breast cancer. He is Chairman of the International Collaborative Cancer Group. This is a multinational trial centre which is based within Imperial College focussing on phase II and phase III studies in breast cancer.

molecular signals controlling aberrant growth of breast cancer cells with specific focus on the oestrogen receptor and allied cell signalling pathways

Dr. Mohamed Fathy Ragab is a consultant radiologist who has completed his graduation in Zagazig Univeristy, Egypt. He then conducted post-graduate studies in Tanta Univeristy, Egypt. He also completed his clinical fellowship in diagnostic radiology. Dr. Ragab completed his PET/CT training in Imperial College, London, UK in 2010. As a pioneer in Molecular Imaging and PET/CT scanning in Egypt, Dr. Ragab has joined many PET/CT unites of specialized oncology centers; including International Medical Center, Maadi Military Medical complex and Al-Galaa Military Medical Complex; in-addition to his working in Agouza hospital and PET/CT unit of TechnoScan Radiology centers’ chain. His name appears on many articles that were published in both National and International Journals. Currently, he is engaged in research studies about Role of PET/CT and Molecular Imaging in Management of Cancer Patients in collaboration with Banha University, Egypt.

PET/CT and Molecular Imaging in detection, staging and re-staging of Cancer, as well as therapy monitoring and prediction of therapeutic response in Cancer patients.

Dr Leandro Castellano is Senior Lecturer in Biochemistry at the University of Sussex in Brighton, and honorary Senior Lecturer at Imperial College London (UK). He obtained a PhD in 2007 at the University “La Sapienza”, Rome, working on the role of microRNAs in solid and liquid cancers. He then moved to Imperial College the same year where he identified for the first time that microRNAs can be regulated by oestrogen receptor alpha (ER-alpha) in ER positive breast cancer which in turn, modulate ER-alpha itself. This regulative miRNA-mRNA network forms a negative feedback loop crucial for breast cancer progression. His research interest focuses on the role of short and long non-coding RNAs in the progression of breast, pancreatic and other solid cancers. He published several articles reporting finding on the role of non-coding RNAs in these diseases using high-throughput sequencing technologies for global discoveries.

Solid cancer, non-coding RNA, gene expression, biological networks in cancer

Gamal EL-Sayed El-Araby Abdelhameed is Vice manager of administration of medical laboratories at Health affairs directorates, Ministry of Health in Egypt. He obtained a PhD in 2014 on “Early detection of Breast Cancer” in Egyptian women and how to make biostatistics for the epidemiology of breast cancer in women in all Egypt . He holds various positions which includes Medical Analysis Specialist, Manager of microbiology lab & Responsible for water treatment units, Researcher, Medical Representative

Pharmacy and medical supply, chemistry and biology, scientific researcher, disaster risk reduction, crisis and conflict prevention, mitigation, resolution and reconciliation

ACHOUR Radhouane is associate professor at faculty of medicine of Tunis-Tunisia; He has published many basic and clinical articles in relation to gynecology and obstetrics. , his research interests include Rare Diseases in gynecology and prenatal diagnosis. He serves as associate professor, Emergency Department of Gynecology and Obstetrics in maternity and neonatology center Tunis Tunisia. He also serves as member of the editorial team for: Asian Pacific Journal of Reproduction, the Global Journal of Rare Diseases, Journal of Neonatal Biology, Current pediatric research, Obstetrics and Gynecology: Open access, Pediatrics and Health Research and Member of the Science Advisory Board.

Breast Pathology, Reproductive Medicine, Gynecology

Dr.Eman Almohawes,is consultatnt diagnostic radiology and women's imaging ,Head of medical imaging department at security forces hospital Dammam Saudi Arabia. As one of the leading figures advocating for early detection and screening of breast cancer for women in Saudi Arabia Eastern province at Saudi cancer foundation , she was the honorary chairperson of the early detection breast cancer campaign 2017 till present organized at May aljaber early cancer detection center. Founder of breast cancer screening program at security forces hospital Dammam established in 2017. Honored for participating and valuable contribution as organizer and speaker in the success of women health and imaging conferences as well as cancer conferences. Honored by Saudi Minister of Health Dr.Tawfeeq AlRabiya for the volunteer participation and work in breast screening at Saudi cancer foundation on international volunteer day 5th /Dec/2017. Member of European society of breast imaging 2018(EUSOBI).

Breast Imaging

Dr.Ghina Berjawi completed her MD and Diagnostic Radiology residency at the American University of Beirut, Lebanon. She then completed her Clinical Fellowship in Breast Imaging and Intervention at King’s College Hospital, London, and MD Anderson Cancer Center, followed by a Clinical Fellowship in MR and Transvaginal Ultrasound Imaging and Interventional Radiology of the Female Genital Tract at Centre Hospitalier Universitaire de Limoges, France. She is also a Fellow of The Royal College of Radiologists (FRCR), London, since 2009. She is currently an Associate Professor of Clinical Diagnostic Radiology and director of the Mamdouha Sayed Bobst Breast Unit at the American University of Beirut Medical Center. Her name appears on over 40 original articles and abstracts, and she has presented at various national and international conferences

Breast Imaging, Women’s Imaging.

Dr Ivan Terziev was born in 1961. He graduated in Medicine in 1987 from the Medical University of Sofia and obtained a specialty in Pathology and Cytology in 1991. Dr Terziev has been working at Tsaritsa Yoanna ISUL University Hospital since 1988, and he is also an Assistant professor of Pathology at the Medical University of Sofia, Bulgaria. Dr Terziev is a member of Bulgarian and European Society of Pathology and Bulgarian-Turkish group on Diseases of Thyroid and Breast. He has numerous publications in Bulgarian scientific journals, as well as more than 20 papers in reputed international ones. Dr Terziev is working in the area of histopathology of head of neck, thyroid gland, gastrointestinal, breast and surgical pathology

Dr Terziev’s research interests include diagnostic and immunohistochemical examination of rare tumors with different localization.

Dr. Kumar received his Ph.D. degree in Neuro-toxicology and is currently a Professor of Biochemistry at The Commonwealth Medical College, Scranton, PA, USA. Dr. Kumar’s research area is focused on the therapeutic targeting of the steroid receptors (SRs) for endocrine-related cancers. Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies. In addition to more than 100 publications to his credit, Dr. Kumar has also served as Editorial Board member of more than two-dozen scientific journals, and as expert reviewer on more than two-dozen grant review panels.

Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies.

Prof. Kathy Qian Luo received BS, MS from Peking University and Ph.D. from the University of British Columbia in Canada. After finishing Postdoc research at California Institute of Technology in USA, she was working as a Visiting Assistant Professor in the Hong Kong University of Science and Technology and an Associate Professor in Nanyang Technological University of Singapore. Prof. Luo now is a Full Professor in the Faculty of Health Sciences at the University of Macau. She has published 70 journal articles with total citations of 2,000 and h-index of 25. She obtained 7 patents from USA, China, and Singapore.

•Cancer research: Identify driver proteins responsible for cancer cell survival in circulation, metastasis, and drug resistance. •Drug discovery: Discover new anti-cancer agents and elucidate their mechanisms of action. •Metabolic diseases: Study diabetes-related endothelial cell death and discover new biomarkers for diabetes diagnosis. •Aging: Generate transgenic zebrafish for studying apoptosis in neuronal and epithelial cells during aging process.

Dr. Shahla Masood is a Persian-born physician, who currently holds the positions of Professor and Chair of the Department of Pathology at University of Florida College of Medicine – Jacksonville and Chief of Pathology and Laboratory Medicine at Shands Jacksonville. She is also the Director of the Pathology Residency Training Program, as well as Cytopathology and Breast Pathology Fellowship Training Program. In addition, Dr. Masood is the Medical Director of Shands Jacksonville Breast Health Center. An internationally recognized expert in breast cancer diagnosis and prognosis, Dr. Masood has fostered the concept of an integrated multidisciplinary approach in breast cancer care, research, and education.

Pathology

Colleen Huber is a Naturopathic Medical Doctor in private practice in Tempe, Arizona. She is Co-Founder and Secretary of the American Naturopathic Research Institute/Naturopathic Oncology Research Institute (ANRI / NORI). She is a Fellow of the Naturopathic Oncology Research Institute. She is a credentialed physician at Plaza Healthcare in Scottsdale, AZ, a 179-bed in-patient, sub-acute facility, where she practices up to the full-scope of practice for naturopathic physicians licensed in Arizona. She graduated from Southwest College of Naturopathic Medicine in Tempe. Her academic writing has appeared in The L ancet and other medical journals.

Breast Cancer

Lei Huo received her Bachelor of Medicine degree at Beijing Medical University and her PhD in Molecular Biology and Genetics at Northwestern University, Chicago. A practicing breast pathologist in MD Anderson Cancer Center, she is actively involved in clinical and translational research in the field of breast cancer. Her research interests include molecular and immunohistochemical markers in the diagnosis and treatment of breast cancer, among others.

Her research interests include molecular and immunohistochemical markers in the diagnosis and treatment of breast cancer, among others

Hiroshi Kobayashi received his Ph.D. in Biochemistry from University of Tokyo in 1974. After his postdoctoral training at Colorado University Medical Center, he started to study adaptation strategies of microorganisms to acidic environments at Chiba University in 1978. His research is focused on mammalian cell functions under acidic conditions from 1996 at Graduate School of Pharmaceutical Sciences, Chiba University. He retired in March 2012 and is a professor emeritus at Chiba University after his retirement. He works as an associate editor of International Immunopharmacology published by Elsevier B.V. from 2014.

Mammalian Cell

A Jain has completed his PhD from Agra University, India. He was a visiting scientist at Texas A&M University. Currently he is a Professor at Albany State University, GA and program coordinator for Biotechnology program. He has received research funding from NIH, DOD and USDA. He served as Director, Center for Undergraduate Research and currently he is serving as MARC U*STAR project director. He has published more than 25 papers in reputed journals and has been serving as reviewer for six journals of international repute.

Cancer Research

Dr. Alvaro Macieira-Coelho is a Research Director at the French National Institute of Health. He received an MD from the University of Lisbon, Portugal, and a PhD from the University of Uppsala Sweden. He made an internship at the University Hospital in Lisbon and was a research associate at the Wistar Institute in Philadelphia (USA) and at the Department of Cell Biology of the University of Uppsala (Sweden). He became Head of the Department of Cell Pathology at the Cancer Institute in Villejuif (France) and was a visiting Professor at the University of Linkoping (Sweden). He published 150 papers in professional Journals and 9 books on cancer and aging. He received the following awards: Fritz Verzar Prize (University of Vienna, Austria), “Seeds of Science”, Career Prize (Lisbon, Portugal), Dr. Honoris Causa (University of Linkoping, Sweden), Johananof International Visiting Professor (Institute Mario Negri, Milano, Italy).

Cancer

He is a Clinic for Senology and Breast Surgery Certified Breast Center.

Cancer

Gilles Freyer is a senior medical oncologist in the Medical Oncology Department of the Centre Hospitalier Lyon-Sud, France and Professor of Oncology at Lyon-Sud University Hospital, a position he has held since 2003. He has become Vice-Dean of the Lyon-Sud University in 2012 and President of the French Collaborative group GINECO in January, 2013. He is also a member of the Gynecologic Cancer Intergroup (GCIG). He is the Medical Director of the Hospices Civils de Lyon Cancer Institute, an institution he has founded in 2014 and which includes around 250 specialists in Oncology

Cancer

Roberto N Miranda has completed his MD at the Universidad Peruana Cayetano Heredia, in Lima, Peru and after emigrating to United States, completed an AP CP Residency at Brown University, fellowship in Hematopathology at Vanderbilt University, and has been Faculty at MD Anderson Cancer Center since 2007, where he is currently working as a Professor in the Department of Hematopathology. He has an interest in T-cell lymphomas and has developed an expertise in breast implant-associated anaplastic large cell lymphoma, a topic on which he has several landmark publications and book chapters, and on which he has lectured nationally and internationally.

Oncology

Hallgeir Rui is a PhD holder and serves as the WBCS Endowed Professor of Breast Cancer Research in the Department of Pathology at the Medical College of Wisconsin, Milwaukee, WI. He has previously held positions at Thomas Jefferson University, Philadelphia, PA, Georgetown University, Washington DC, and Uniformed Services University, Bethesda, MD. He completed his Post-doctoral training at NCI, Frederick, MD and Moffitt Cancer Center, Tampa, FL. He received his MD and PhD degrees at the University of Oslo, Norway. His laboratory research is centered on analyses of human breast cancer to improve tailored therapy.

Oncology

Feng Yan is the Vice Director of Department of Clinical Laboratory in Nanjing Medical University Affiliated Cancer Hospital and Jiangsu Cancer Hospital. The research works focus on the Bioanalytical Chemistry in laboratory medical diagnostics, particularly in detection of tumor markers and tumor cells. She has published 42 papers in SCI journals.

Oncology

Dr.Sveta Silverman ,MD, FRCP Associate Professor The Department of Pathology and Laboratory Medicine University of Alberta

Pathology and Laboratory Medicine

Dr Rani Kanthan is a consultant Anatomical pathologist in the Dept. of Pathology & Laboratory Medicine at the University of Saskatchewan with a focused interest in surgical oncology including breast and gastrointestinal tract. She has published more than 100 peer reviewed manuscripts that are indexed in PubMed /Google scholar and serves as an editorial board member in various journals. She is an active educator and continues to participate and present at various national and international meeting.

Yvone Paterson is Professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, USA. As a Professor of Microbiology, Paterson is an active educator and trainer and is the PI of several training grants and programs. Her research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system. She has pioneered the application of this organism in vaccine development for over 20 years. Her laboratory was the first to show that this bacterium could be genetically engineered to target antigens to the MHC class I pathway for antigen processing with the induction of cytotoxic T cells, the first to show that it could provide protective immunity against viral challenge and the first to apply the technology for the immunotherapy of cancer. In partnership with Advaxis Inc., a company she founded in 2002, the Listeria based technology is now in a number of clinical trials. Overall, these trials have shown that Listeria based immunotherapeutics are safe to use in humans and result in significantly prolonged survival and, in some cases, complete and partial remissions.

Yvone Paterson research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system.

Dr. Shahla Masood is a Persian-born physician, who currently holds the positions of Professor and Chair of the Department of Pathology at University of Florida College of Medicine – Jacksonville and Chief of Pathology and Laboratory Medicine at Shands Jacksonville. She is also the Director of the Pathology Residency Training Program, as well as Cytopathology and Breast Pathology Fellowship Training Program. In addition, Dr. Masood is the Medical Director of Shands Jacksonville Breast Health Center. An internationally recognized expert in breast cancer diagnosis and prognosis, Dr. Masood has fostered the concept of an integrated multidisciplinary approach in breast cancer care, research, and education.

Pathology

Amila Orucevic obtained MD degree from Medical School of University of Sarajevo, Bosnia and Herzegovina (1983) and PhD from The University of Western Ontario, London, Ontario, Canada (1996). She is a board certified pathologist for Anatomic and Clinical Pathology by The American Board of Pathology (2002), and board certified pathologist for Anatomic Pathology by The Royal College of Physicians and Surgeons of Canada (2002). Currently, she is Attending/Staff pathologist, Associate Professor, and Director of Research at the Department of Pathology, The University of Tennessee Medical Center, Knoxville, TN, USA. She published 21 papers in reputed peer reviewed journals.

Pathology, Breast Cancer

Colleen Huber is a Naturopathic Medical Doctor in private practice in Tempe, Arizona. She is Co-Founder and Secretary of the American Naturopathic Research Institute/Naturopathic Oncology Research Institute (ANRI / NORI). She is a Fellow of the Naturopathic Oncology Research Institute. She is a credentialed physician at Plaza Healthcare in Scottsdale, AZ, a 179-bed in-patient, sub-acute facility, where she practices up to the full-scope of practice for naturopathic physicians licensed in Arizona. She graduated from Southwest College of Naturopathic Medicine in Tempe. Her academic writing has appeared in The L ancet and other medical journals.

Breast Cancer

Raj Kumar received his PhD degree in Neuro-toxicology and is currently a Professor of Biochemistry at The Commonwealth Medical College, Scranton, PA, USA. His research area is focused on the therapeutic targeting of the steroid receptors (SRs) for endocrine-related cancers. Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies. In addition to more than 100 publications to his credit, he has also served as Editorial Board Member of more than two-dozen scientific journals, and as expert reviewer on more than two-dozen grant review panels.

Therapeutic targeting of the steroid receptors (SRs) for endocrine-related cancers

Lei Huo received her Bachelor of Medicine degree at Beijing Medical University and her PhD in Molecular Biology and Genetics at Northwestern University, Chicago. A practicing breast pathologist in MD Anderson Cancer Center, she is actively involved in clinical and translational research in the field of breast cancer. Her research interests include molecular and immunohistochemical markers in the diagnosis and treatment of breast cancer, among others.

Her research interests include molecular and immunohistochemical markers in the diagnosis and treatment of breast cancer, among others

A Jain has completed his PhD from Agra University, India. He was a visiting scientist at Texas A&M University. Currently he is a Professor at Albany State University, GA and program coordinator for Biotechnology program. He has received research funding from NIH, DOD and USDA. He served as Director, Center for Undergraduate Research and currently he is serving as MARC U*STAR project director. He has published more than 25 papers in reputed journals and has been serving as reviewer for six journals of international repute.

Cancer Research

Jin Cheng has completed his MD and PhD from Beijing Capital Medical University and Paris University XIII in 1986 and 1994, respectively. Following his postdoctoral training at Fox Chase Cancer Center in Philadelphia, he was recruited by Moffitt Cancer Center as an assistant professor in 1997. Currently, he is professor and interim chair of Deportment of Molecular Oncology at Moffitt Cancer Center. He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.

He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.

Yutaka Tsutsumi graduated from Keio University School of Medicine, Tokyo in 1976, and completed his PhD in 1982. He is the certified pathologist, the certified cytologist and the infection control doctor. He worked for the Department of Pathology, Tokai University School of Medicine, Isehara, Japan for 21 years, and in 2001 he moved as a professor to the Department of Pathology, Fujita Health University School of Medicine, Toyoake, Japan. Dr. Tsutsumi, an oboe player, has published more than 200 English-written papers in varied journals, and released plural single-authored textbooks and web sites in the field of pathology and infectious diseases

Cancer, Pathology

Professor Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 150 research publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books

Research interests: Our nanomedicine laboratory of immunology and molecular biomedical research (NLIMBR) is discovering the novel and safe targeted nanomedicine based nano-nutraceuticals for cancers, autoimmune disorders and inflammatory diseases.

Founder of the first Breast Specialty clinic in the Eastern Province of Saudi Arabia 2000 and the Breast Oncology Clinic 2009. Pioneer & Founder of the University of Dammam Scientific Chair for Intraoperative Radiotherapy treatment for breast cancer 2010 rendering the University of Dammam the first institution in the region to acquire such an advanced treatment modality.

Prof. Abdel Hadi has contributed to the field of breast diseases by many publications in both national and international journals

Hiroshi Kobayashi received his Ph.D. in Biochemistry from University of Tokyo in 1974. After his postdoctoral training at Colorado University Medical Center, he started to study adaptation strategies of microorganisms to acidic environments at Chiba University in 1978. His research is focused on mammalian cell functions under acidic conditions from 1996 at Graduate School of Pharmaceutical Sciences, Chiba University. He retired in March 2012 and is a professor emeritus at Chiba University after his retirement. He works as an associate editor of International Immunopharmacology published by Elsevier B.V. from 2014.

Mammalian Cell

Federico Cattin has completed his graduation at the age of 25 in the Udine University, and post-graduate studies in the Surgical Department of the same University. He is engaged in the studies about breast cancer and has attended a scholarship in the European Institute of Oncology (IEO) in Milan, held by Prof. Umberto Veronesi. He has published 13 papers in reputed journals. Nowadays he works in the Sterzing General hospital in South Tyrol, in Italy

Breast cancer

Diptendra K Sarkar is the Chief of the Breast Service and Research Unit at IPGMER, Kolkata, India. He is a Founder member and presently the Honorary Secretary of The Association of Breast Surgeons of India. He has delivered more than 150 lectures and orations in various national and international conferences. He has published more than 30 articles and has contributed as author to two different text books. He is the Associate Editor of Indian Journal of Surgery and Surgical Oncology. He is part of the esteemed Governing Council of Association of Surgeons of India. He is the one of the pioneers of Breast Surgery in Eastern India.

Breast Cancer

Dr. Elias is focused on clinical breast cancer research and is the director of the clinical breast oncology program. This comprehensive program includes a weekly multi-disciplinary clinic and tumor board, a hereditary clinic, benign breast complaint clinic, a screening and breast imaging program, in addition to daily breast specialty oncology clinics. The sarcoma program includes consult/new patient clinics as well as followups. Dr. Elias is the principal investigator on numerous national and local therapeutic trials and is institution PI for the SWOG grant. He is a member of the SWOG breast committee. He is also the Associate Director of the Cancer Center for clinical sciences and oversees the Clinical Investigations Core.

breast imaging program, clinical breast cancer research

Dr. Shahla Masood is a Persian-born physician, who currently holds the positions of Professor and Chair of the Department of Pathology at University of Florida College of Medicine – Jacksonville and Chief of Pathology and Laboratory Medicine at Shands Jacksonville. She is also the Director of the Pathology Residency Training Program, as well as Cytopathology and Breast Pathology Fellowship Training Program. In addition, Dr. Masood is the Medical Director of Shands Jacksonville Breast Health Center. An internationally recognized expert in breast cancer diagnosis and prognosis, Dr. Masood has fostered the concept of an integrated multidisciplinary approach in breast cancer care, research, and education.

Breast Cancer Pathology

Amy Levi is currently the Director of the Interdepartmental Nurse-Midwifery Education Program at the University of California San Francisco. This unique program is situated in both the Schools of Medicine and Nursing, and draws from both disciplines to provide graduate education in midwifery and women’s health to registered nurses. She is a founding member of the Center for Women’s Health and Empowerment for the University of California Global Health Institute, and is the liaison to the Global Health Clinical Scholars Program which provides an introduction to global health for students from each of the four health professional schools at UCSF. Dr. Levi is the Clinical Education Consultant for the Health Workforce Pilot Project in the State of California, a study which is evaluating the training trajectory and clinical outcomes of nurse-midwives, nurse practitioners, and physician assistants providing vacuum aspiration abortion care.

Global women’s health, options in reproductive health care, and health care provider education.

2007-present Clinical Associate Professor Department of Obstetrics and Gynecology Stanford University Medical Center Stanford, California 2003-2007 Clinical Assistant Professor Department of Obstetrics and Gynecology Stanford University Medical Center Stanford, California 2000-2003 Assistant Clinical Professor Department of Family and Community Medicine University of California, San Francisco San Francisco, California 1993-1995 Clinical Instructor of Medicine Harbor General Hospital UCLA School of Medicine Division of Endocrinology Torrance, California 1993-1995 Clinical Preceptor Presbyterian Intercommunity Hospital USC Family Practice Residency Program Whittier, California

Endocrinology & Metabolism

Dr. Stachenfeld is an Associate Fellow at the John B. Pierce Laboratory and an Associate Professor of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine. My primary research focus is the impact of reproductive hormones on physiological responses to environmental challenges in women. To this end, my work has emphasized fluid regulatory and cardiovascular responses to exercise and temperature exposure.

Our current studies focus on reproductive hormone effects on blood pressure control, autonomic function and endothelial function.

Mr Ragheed Al-Mufti is Chairman of the West of London Breast Cancer Network. He is also Consultant Breast, Endocrine and Oncological Surgeon at St Mary's Hospital, London, and Honorary Senior Lecturer at Imperial College London School of Medicine (2005 to current). He is a former Consultant in Breast, Endocrine & Oncological Surgery at St Bartholomew's and the Royal London Hospitals (2001 to 2005), and Former Senior Lecturer and Consultant Oncological Surgeon at University College London and Whittington Hospitals (1998 to 2001). Surgical training : Senior Surgical Registrar, Career Surgical Registrar and Surgical Research Registrar, London and North East Thames Region, Bristol & Exeter Surgical SHO Notation. Societies:- Elected Member of the National Executive Committee of BASO (Association of Cancer Surgery) - Member of the Association of Surgeons of Great Britain and Ireland - Member of the Association of Breast Surgeons at BASO - Member of the Thames Cancer Registry Advisory Board - Surgical Tutor of the Royal College of Surgeons of England - Examiner for University of London (Imperial College London and University College London).

Breast and endocrine cancers (surgery)

Parmjit Jat undertook his PhD at the Imperial Cancer Research Fund (now CRUK) and Imperial College London from 1978-1982. This was followed by Postdoctoral research at the MIT Centre for Cancer Research in the laboratory of Dr Philip Sharp. From 1987 to 2003 he was a Group Leader at the UCL Branch of the Ludwig Institute for Cancer Research. Since 2003, he has been a Professor of Molecular Cell Biology at the UCL Institute of Neurology and a member of the MRC Prion Unit.

Breast Cancer biology

The research in my laboratory is focused on understanding signaling networks within cells and how these signaling events modulate gene expression and proliferation. Extracellular signals are routed through signaling networks where they can activate multiple pathways, integrate at different levels, and form positive and negative feedback loops. The laboratory uses a combination of computational modeling and experimental biology to gain a systems understanding of the network and how it regulates gene expression and proliferation.

computational modeling to biochemical analysis of signaling events to proteomics using reverse phase high density lysate microarrays

Jerzy Gubernator studied Biotechnology at Wroclaw University and then has completed his PhD from the same University, Faculty of Biotechnology. Now He is the Head of Department of Lipids and Liposomes at the Faculty of Biotechnology and the director of Academic Center for Biotechnology of Lipid Aggregates in Wroclaw. His main field of investigation are liposomal drug delivery systems. Hi is also specializing in bi functional active drug loading methods. He has published more than 20 papers concerning liposomes and liposomal technology.

Role of Lipids and Liposomes in Breast cancer

Yutaka Tsutsumi graduated from Keio University School of Medicine, Tokyo in 1976, and completed his PhD in 1982. He is the certified pathologist, the certified cytologist and the infection control doctor. He worked for the Department of Pathology, Tokai University School of Medicine, Isehara, Japan for 21 years, and in 2001 he moved as a professor to the Department of Pathology, Fujita Health University School of Medicine, Toyoake, Japan. Dr. Tsutsumi, an oboe player, has published more than 200 English-written papers in varied journals, and released plural single-authored textbooks and web sites in the field of pathology and infectious diseases

Cancer, Pathology

Hiroshi Kobayashi received his Ph.D. in Biochemistry from University of Tokyo in 1974. After his postdoctoral training at Colorado University Medical Center, he started to study adaptation strategies of microorganisms to acidic environments at Chiba University in 1978. His research is focused on mammalian cell functions under acidic conditions from 1996 at Graduate School of Pharmaceutical Sciences, Chiba University. He retired in March 2012 and is a professor emeritus at Chiba University after his retirement. He works as an associate editor of International Immunopharmacology published by Elsevier B.V. from 2014.

Mammalian Cell

Professor Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 150 research publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books

Our nanomedicine laboratory of immunology and molecular biomedical research (NLIMBR) is discovering the novel and safe targeted nanomedicine based nano-nutraceuticals for cancers, autoimmune disorders and inflammatory diseases.

Federico Cattin has completed his graduation at the age of 25 in the Udine University, and post-graduate studies in the Surgical Department of the same University. He is engaged in the studies about breast cancer and has attended a scholarship in the European Institute of Oncology (IEO) in Milan, held by Prof. Umberto Veronesi. He has published 13 papers in reputed journals. Nowadays he works in the Sterzing General hospital in South Tyrol, in Italy

Breast cancer

Dr. Makoto Emoto is the Professor of International University of Health and Welfare in Japan and the Director of Gynecology in Center for Preventive Medicine, Sanno Hospital, Fukuoka, Japan and the former Professor of Fukuoka University Hospital. He received his Ph.D. Degree in 1992 from Fukuoka University Medical School. He was the Research Associate in Department of Obstetrics & Gynecology and Pathology in Cambridge University and St. Edmonds College 2000-2002 and in Cell Biology in Harvard University Medical School 2002. He has authored more than 40 publications in leading journals, especially in Gynecologic Oncology and Ultrasound. He is the Board Certified Fellow of the Japan Society of Gynecologic Oncology, Japan Society of Clinical Oncology, and the Japan Society of Ultrasonics in Medicine.

Gynecologic Oncology, Cancer Stem Cell, Angiogenesis, Ultrasound Imaging, Ultrasound Therapy, Drug Delivery System

Dr. Shahla Masood is a Persian-born physician, who currently holds the positions of Professor and Chair of the Department of Pathology at University of Florida College of Medicine – Jacksonville and Chief of Pathology and Laboratory Medicine at Shands Jacksonville.She is the founder and Editor-in-Chief of The Breast Journal, the founder and past president of the “International Society of Breast Pathology,” the Director of the “Annual Multidisciplinary Symposium on Breast Disease”, “The Breast Cancer Public Forum”, and is currently the President of “The World Society for Breast Health.” She has been named as one of the Top Doctors in America and one of the 20 Top Professors in Oncology at an international level. Dr. Masood is a patient advocate, a partner in community affairs and an accomplished artist and gourmet chef.

She is the founder and Editor-in-Chief of The Breast Journal, the founder and past president of the “International Society of Breast Pathology,” the Director of the “Annual Multidisciplinary Symposium on Breast Disease”, “The Breast Cancer Public Forum”, and is currently the President of “The World Society for Breast Health.”

Marie Wood, MD is professor of medicine, deputy director of the hematology/Oncology Division and director of the Familial Cancer Program. She is a member of the ASCO Prevention Subcommittee and Vice Chair for the CALGB/AIIiance Prevention Committee. Dr. Wood's research focuses around cancer genetics and breast cancer prevention. She has done studies on the barriers to utilization of cancer genetics by primary care providers and recent work has focused on the definition of an adequate family history for oncology professionals. Dr. Wood has received national and local funding to evaluate the link between breast density and vitamin D in women at risk for breast cancer. She is chair of a national (CALGB/AIIiance) study evaluating this effect. Additional studies focus on risk factors for breast cancer and chemoprevention studies of the effects of statins on breast cancer biomarkers such as breast density, various serum and tissue biomarkers.

She is chair of a national (CALGB/AIIiance) study evaluating this effect. Additional studies focus on risk factors for breast cancer and chemoprevention studies of the effects of statins on breast cancer biomarkers such as breast density, various serum and tissue biomarkers.

Yvone Paterson is Professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, USA. As a Professor of Microbiology, Paterson is an active educator and trainer and is the PI of several training grants and programs. Her research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system. She has pioneered the application of this organism in vaccine development for over 20 years. Her laboratory was the first to show that this bacterium could be genetically engineered to target antigens to the MHC class I pathway for antigen processing with the induction of cytotoxic T cells, the first to show that it could provide protective immunity against viral challenge and the first to apply the technology for the immunotherapy of cancer. In partnership with Advaxis Inc., a company she founded in 2002, the Listeria based technology is now in a number of clinical trials. Overall, these trials have shown that Listeria based immunotherapeutics are safe to use in humans and result in significantly prolonged survival and, in some cases, complete and partial remissions.

Yvone Paterson research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system.

Professor Khan is Professorial Fellow at the Department of Medicine, University of Melbourne; and School of Public Health and Preventative Medicine, Monash University. She is the Director of the Rehabilitation Services at the Royal Melbourne Hospital. She completed her specialist training in Rehabilitation Medicine in 2000 and ‘Doctor of Medicine’ in 2009. She is a Representative for the Western Pacific Region WHO, ICF Research Branch; Executive member of the WHO International Disaster Committee and Task Force Lead, Committee for Rehabilitation Disaster Relief, ISPRM. She currently holds 9 international academic research appointments in Europe and US. She has a leadership role in rehabilitative care and research, and has published over 250 scientific papers (including 14 Cochrane reviews, 12 book chapters), and is invited speaker at national and international conferences (over 50 presentations in last 5 years).

he has a leadership role in rehabilitative care and research, and has published over 250 scientific papers (including 14 Cochrane reviews, 12 book chapters), and is invited speaker at national and international conferences.

Aysegul A. Sahin is a Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center. she has done Degree-Granting Education in 1980 at University of Ankara School of Medicine, Ankara, Turkey.

Aysegul A. Sahin is a Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center.

P Raghu Ram is amongst the few in the World to have acquired prestigious FRCS from all four Royal Colleges in British Isles (London, Edinburgh, Glasgow, Ireland) & FACS from American College of Surgeons. Having obtained First Place in MS Postgraduate Examination, he completed Subspecialty training in Breast Surgery at world renowned Centers of excellence in the UK. He is the youngest ever recipient of the International Gold Medal (2013) in the 508 years history of the Royal College of Surgeons of Edinburgh.

He is the youngest ever recipient of the International Gold Medal (2013) in the 508 years history of the Royal College of Surgeons of Edinburgh.

Zeina Nahleh is currently Professor of Internal Medicine and Chief of the Division of Hematology-Oncology at the Texas tech Health Sciences Center in El Paso, TX. She is also Co-Director of the Texas Tech Garbar Breast Care Center and Chairperson of the University Medical Center (UMC) Cancer Committee. DR Nahleh was previously employed as Associate Professor and Co-Leader of the Breast Cancer Multidisciplinary team at the Wayne State University- Barbara Ann Karmanos Cancer Institute, aNational Cancer Institute(NCI) - designated Cancer Center. Dr Nahleh’ s research interests, funded by the National Cancer Institute (NCI), the Cancer Prevention Institute of Texas (CPRIT) and several scientific agencies, focus on innovative treatment of breast cancer and improvingthe quality of life of cancer patients. Dr Nahleh is a principal investigator in the Southwest Oncology Group (SWOG) and a member of the NCI- Neoadjuvant and Metastatic breast committees. She is also a member of the American Society of Clinical Oncology and the American College of Physicians. Dr Nahleh has received numerous awards including the Barbara Ann Karmanos‘sHero of Breast Cancer Award, and the TTUHSC –EP Dean’s Excellence in Research Award. She has authored over 50 articles, books and book chapters in the field of cancer and breast cancer research. She has presented in major national and international cancer meetings and serves on the editorial board of numerous world -renowned medical journals.

Nahleh’s research interests, funded by the National Cancer Institute (NCI), the Cancer Prevention Institute of Texas (CPRIT) and several scientific agencies, focus on innovative treatment of breast cancer and improvingthe quality of life of cancer patients.

Alahari Suresh obtained his Bachelor of Science in Biology and Master of Science in Human Genetics from India in 1983 and 1986 respectively. His Ph.D. in Molecular Biology was awarded by Drexel University, Philadelphia in the year 1994. From 1994 to 1998, Dr. Alahari did a post-doctoral fellowship at the University of North Carolina at Chapel Hill. Since 1998, he has been a faculty member at the University of North Carolina and in 2004 joined the LSUHSC as Associate Professor of the Department of Biochemistry. During his tenure at the University of North Carolina, he discovered a novel protein that he termed, Nischarin. Dr. Alahari has published several papers describing the function of Nischarin. He has served on editorial review boards and study sections. In addition he availed visiting professorships at the University of Pennsylvania, Philadelphia and Rockefeller University, New York. Currently he holds endowed professorship named Fred Brazda Professorship.

He has served on editorial review boards and study sections. In addition he availed visiting professorships at the University of Pennsylvania, Philadelphia and Rockefeller University, New York. Currently he holds endowed professorship named Fred Brazda Professorship.

Dr. Henry Lynch established Creighton's Hereditary Cancer Prevention Clinic in 1984, an interdisciplinary clinic where families can find information and services related to all hereditary cancers. Dr. Lynch had the idea to look at cancer from a genetics perspective (he postulated that cancer could be hereditary) rather than focusing exclusively from an environmental point of view (which at the time was the only acceptable cause for cancer in the medical circles). This idea became the main focus of his research for years to come. Dr. Lynch developed what are today regarded as the cardinal principles of cancer genetics: early age of onset of the disease, specific pattern of multiple primary cancers, and Mendelian patterns of inheritance in hundreds of extended families worldwide.

Dr. Lynch developed what are today regarded as the cardinal principles of cancer genetics: early age of onset of the disease, specific pattern of multiple primary cancers, and Mendelian patterns of inheritance in hundreds of extended families worldwide.

Yan-gao Man holds a medical doctor degree in Western Medicine and Master degree in Cell Biology and Microbiology from China, and a PhD in Cell Biology and Anatomy from USA. He received postdoctoral training in Cancer Biology at the American National Cancer Institute. After receiving his PhD in 1998, he has authored and co-authored over 200 published scientific and 46 non-scientific articles, and received 18 research grants and 3 patent certificates. He served as the Director of Gynecologic and Breast Research Laboratory of Armed Forces Institute of Pathology and American Registry of Pathology from 1995 to 2011. Currently, he serves as the Director of Research Laboratory and International Collaboration at Bon Secours Cancer Institute. He is also the editor-in-chief of a SCI (Journal of Cancer) and four newly launched international medical journals. His main research interest focuses on the mechanism of cancer invasion and metastasis. He is the author of the world most updated theories for cancer invasion and metastasis. His theory of cancer invasion has been regarding as more compatible with existing data than the traditional theory. Among all major theories of cancer metastasis, his theory is the only one that can explain all steps of metastasis.

Yan-gao Man main research interest focuses on the mechanism of cancer invasion and metastasis.

Dr Azim is a Professor of Clinical Oncology and immediate past chairman of the Department of Clinical Oncology, Faculty of Medicine, Cairo University. He is the president of the Cairo Oncology Center, one of the largest private Cancer centers in the Middle East region. Dr Azim chairs the scientific committee of the NCCN Middle East chapter and is a member of numerous societies, including the ASCO, ASH, ESMO, ASTRO and the European Blood and Marrow Transplantation Society. He has been principal investigator for many multicenter clinical trials and has published more than 80 papers and he was the chief editor of 2 educational books ( ASCO – PANARAB Lymphoma Conference (1999) and the MD Anderson Cancer Centre / Cairo University joint meeting (2006). Dr Azim serves as a referee for the Annals of Oncology Journal, THE BREAST, BMC Cancer, Chemotherapy journal , Advances in Cancer Research & Treatment, Journal of the Egyptian National Cancer Institute, and the Chinese Clinical Oncology Journal.

He has been principal investigator for many multicenter clinical trials and has published more than 80 papers and he was the chief editor of 2 educational books ( ASCO – PANARAB Lymphoma Conference (1999) and the MD Anderson Cancer Centre / Cairo University joint meeting (2006).

Robert-Alain Toillon has completed his PhD at the age of 28 years from Lille University and postdoctoral studies from Université Libre de Bruxelles. He is the director of “Neurotrophin signaling and therapy resistance” team in INSERM U908 lab. He was hired as cell biology professor of Lille University in 2013 and published more than 30 papers in reputed journals.

He was hired as cell biology professor of Lille University in 2013 and published more than 30 papers in reputed journals.

Jin Cheng has completed his MD and PhD from Beijing Capital Medical University and Paris University XIII in 1986 and 1994, respectively. Following his postdoctoral training at Fox Chase Cancer Center in Philadelphia, he was recruited by Moffitt Cancer Center as an assistant professor in 1997. Currently, he is professor and interim chair of Deportment of Molecular Oncology at Moffitt Cancer Center. He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.

He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.

Dr. Kumar received his Ph.D. degree in Neuro-toxicology and is currently a Professor of Biochemistry at The Commonwealth Medical College, Scranton, PA, USA. Dr. Kumar’s research area is focused on the therapeutic targeting of the steroid receptors (SRs) for endocrine-related cancers. Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies. In addition to more than 100 publications to his credit, Dr. Kumar has also served as Editorial Board member of more than two-dozen scientific journals, and as expert reviewer on more than two-dozen grant review panels.

Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies.

Merdan Fayda is an associate professor at Istanbul University, Institute of Oncology, Dept. Of Radiation Oncology. He has been working in the field of radiation oncology since 1999, when he began his education at Istanbul University‘s Institute of Oncology Dept. of Radiation Oncology. Since then, Dr. Fayda has been involved with the Italian Hospital Dept. of Radiation Oncology, Gulhane Military Medical Academy, Dept. of Radiation Oncology, Kocaeli University Faculty of Medicine, Department of Radiation Oncology, and his current affiliation with Istanbul University Institute of Oncology, Department of Radiation Oncology. Dr. Fayda is a member of the Turkish Society of Radiation Oncology, ASTRO and ESTRO. He has several publications which include his thesis on Patient and treatment related factors affecting locoregional recurrence after post-mastectomy adjuvant radiotherapy’, Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer and his most recent publication of The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer.

Dr. Fayda is a member of the Turkish Society of Radiation Oncology, ASTRO and ESTRO. He has several publications which include his thesis on Patient and treatment related factors affecting locoregional recurrence after post-mastectomy adjuvant radiotherapy’, Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer and his most recent publication of The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer

Professor Weightman is an experimental physicist with a track record in developing novel instruments. He was a co-applicant on the proposal to construct the ALICE machine which is an energy recovery linear accelerator, the first of its kind in Europe and the only one in the world equipped with a terahertz beamline designed for studies of cancer. ALICE is now operational and Weightman is leading a collaborative programme involving academic scientists and clinicians in exploiting the potential of ALICE for cancer research.

Weightman is leading a collaborative programme involving academic scientists and clinicians in exploiting the potential of ALICE for cancer research.